Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126514
Clinical perspectives on human genetic screening to prevent nevirapine toxicity
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Nevirapine is one of the most extensively prescribed antiretroviral drugs worldwide. However, a concern is increased risk for severe toxicity when antiretroviral-naive individuals with higher CD4 T-cell counts initiate nevirapine-containing regimens. Several genetic variants are associated with nevirapine toxicities. The authors used data from a previous study to anticipate potential consequences of genetic screening to prevent nevirapine adverse events. That study enrolled cohorts of African, Asian and European descent in 11 countries, including 276 patients who had experienced severe cutaneous and/or hepatic adverse events with nevirapine-containing regimens and 587 matched nevirapine-tolerant controls. Associations were identified with HLA-Cw*04, HLA-B*35, HLA-DRB*01 and CYP2B6 516G>T (rs3745274); however, positive predictive values for these genetic markers were low, and most nevirapine-associated adverse events occurred in patients without these markers. Unless better genetic predictors are identified, nevirapine toxicity is best avoided by continuing to follow current prescribing guidelines that are based largely on CD4 T-cell criteria.
Matèries
Matèries (anglès)
Citació
Citació
HAAS, David w., MOOTSIKAPUN, Piroon, RUXRUNGTHAM, Kiat, PODZAMCZER PALTER, Daniel, Nevirapine Toxicogenomics Study Team. Clinical perspectives on human genetic screening to prevent nevirapine toxicity. _Personalized Medicine_. 2012. Vol. 9, núm. 7, pàgs. 773-782. [consulta: 20 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/126514]